ArticleAlimentary pharmacology & therapeutics2026
Prevalence and Burden of Fatigue Across Disorders of Gut-Brain Interaction: Results From the Rome Foundation Global Epidemiology Study.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: Fatigue in Disorders of Gut-Brain Interaction-An Important Symptom to Recognise.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOverlap among disorders of gut-brain interaction (DGBI) is common, with many patients experiencing concomitant non-gastrointestinal symptoms. Fatigue is frequently reported, yet population-based prevalence estimates across DGBI are limited.
aimsTo examine the prevalence and burden of fatigue among DGBI.
methodsData were derived from the Rome Foundation Global Epidemiology Study's internet-based survey, conducted in 26 countries using the Rome IV Adult Diagnostic Questionnaire. Fatigue was assessed with single items from the Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 and the Patient Health Questionnaire-12 (PHQ-12). Prevalence of fatigue was compared across three groups, including no DGBI, one DGBI and multiple DGBI, with potential associated factors examined using logistic regression.
resultsAmong 54,127 participants (49% female; mean age 44 years), 59.9% had no DGBI, 26.6% had one DGBI and 13.5% had multiple DGBI. Fatigue prevalence was higher with more DGBI overlap: PROMIS 7.7% (95% CI:7.46-8.04), 16.4% (95% CI: 15.79-17.00), 30.2% (95% CI: 29.16-31.26); PHQ-12 12.6% (95% CI: 12.24-12.96), 25.8% (95% CI: 25.06-26.49), 42.0% (95% CI: 40.83-43.09) for no, one, and multiple DGBI. Fatigue was most common in reflux hypersensitivity (PROMIS 46%, PHQ-12 58%) and irritable bowel syndrome (PROMIS 39%, PHQ-12 53%). Among individuals with DGBI, fatigue was consistently associated across both definitions with female sex, age, BMI, sleep disturbance, higher anxiety and depression scores, greater somatic symptom burden, lower psychological well-being, antidepressant use, and satiety, abdominal pain, and bloating.
conclusionsFatigue is common and burdensome in DGBI, particularly with overlapping diagnoses. Given the cross-sectional design, directionality between fatigue and DGBI symptom burden remains unclear. Future research should employ longitudinal fatigue assessments to inform targeted management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.